PROGNOSTIC SIGNIFICANCE OF CLINICAL AND LABORATORY INDICATORS IN PATIENTS WITH CHRONIC HEART FAILURE
Keywords:
Chronic heart failure, prognostic markers, NT-proBNP, cardiovascular mortality, clinical cardiology, Andijan region, left ventricular ejection fraction, disease progressionAbstract
Chronic heart failure remains a progressive and ultimately fatal syndrome, representing a massive burden on the healthcare system of the Republic of Uzbekistan. This prospective observational study investigates the specific prognostic value of clinical, echocardiographic, and laboratory indicators in predicting adverse cardiovascular outcomes among patients with chronic heart failure residing in the Andijan region. A cohort of 420 patients with established chronic heart failure (NYHA functional classes II-IV) was continuously monitored over an 18-month period at regional cardiological centers. The study evaluated conventional clinical metrics alongside advanced biomarkers, specifically N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hs-CRP), and the estimated glomerular filtration rate. The empirical results demonstrated that while traditional symptoms and the six-minute walk test provided foundational functional data, they lacked sufficient sensitivity for predicting imminent decompensation. Conversely, elevated baseline NT-proBNP levels (exceeding 1200 pg/mL), reduced left ventricular ejection fraction (below 35%), and the presence of subclinical renal dysfunction emerged as the most potent, independent predictors of hospital readmission and cardiovascular mortality. The discussion contextualizes these findings within the local epidemiological landscape of the Fergana Valley, emphasizing issues such as medication adherence and the late clinical presentation of ischemic heart disease. The study concludes that the routine integration of molecular biomarkers, specifically NT-proBNP, into standard regional cardiological protocols is imperative for accurately stratifying risk, optimizing guideline-directed medical therapy, and ultimately reducing the high rates of re-hospitalization among the vulnerable heart failure population in Andijan.
References
1.Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G., Coats, A. J., ... & van der Meer, P. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 37(27), 2129-2200.
2.McMurray, J. J., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., ... & Ponikowski, P. (2012). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Heart Journal, 33(14), 1787-1847.
3.Januzzi, J. L., van Kimmenade, R., Lainchbury, J., Bayes-Genis, A., Ordonez-Llanos, J., Santalo-Bel, M., ... & Richards, M. (2006). NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. European Heart Journal, 27(3), 330-337.
4.Fonarow, G. C., Adams, K. F., Abraham, W. T., Yancy, C. W., & Boscardin, W. J. (2005). Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA, 293(5), 572-580.
5.Heywood, J. T., Fonarow, G. C., Costanzo, M. R., Mathur, V. S., Wigneswaran, J. R., & Wynne, J. (2007). High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. Journal of Cardiac Failure, 13(6), 422-430.
6.Anand, I. S., Latini, R., Florea, V. G., Kuskowski, M. A., Rector, T., Masson, S., ... & Cohn, J. N. (2005). C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation, 112(12), 1428-1434.
7.O'Meara, E., Clayton, T., McEntegart, D. J., McMurray, J. J., Piña, I. L., Granger, C. B., ... & Pocock, S. J. (2006). Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program. Circulation, 113(7), 986-994.
8.Khodjaeva, D. T. (2020). Epidemiology of cardiovascular diseases in Uzbekistan: Current status and the impact of urbanization. Central Asian Journal of Medical Sciences, 6(2), 45-52.
9.Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., ... & Wilkoff, C. E. (2013). 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 62(16), e147-e239.
10.Felker, G. M., Leimberger, J. D., Califf, R. M., Cuffe, M. S., Massie, B. M., Adams, K. F., ... & O'Connor, C. M. (2004). Risk stratification after hospitalization for decompensated heart failure. Journal of Cardiac Failure, 10(6), 460-466.




United Kingdom
Germany
France
Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo
Italy
Spain
Poland
Netherlands
Belgium
Sweden
Norway
Finland
Denmark
Switzerland
Austria
Czech Republic
Hungary
Romania
Bulgaria
Greece
Portugal